M&A - COLLEGIUM PHARMACEUTICAL, INC

Form Type: DEF 14A

Filing Date: 2025-03-28

Corporate Action: Acquisition

Type: New

Accession Number: 000155837025003983

Filing Summary: Collegium Pharmaceutical, Inc. filed a definitive proxy statement outlining the upcoming 2025 Annual Meeting of Shareholders scheduled for May 15, 2025. The document highlights significant corporate developments from 2024, including the acquisition of Ironshore Therapeutics, which added Jornay PM, a treatment for ADHD, to Collegium's portfolio. This acquisition is expected to diversify the business beyond chronic pain management and is supported by a $646 million financing deal that positioned the company for strategic growth. Collegium's financial performance included record revenues of $631.4 million and a strong commitment to returning capital to shareholders, with $60 million repurchased in shares and $197 million returned over time. The proxy statement presents six agenda items for the upcoming meeting, including the election of directors and the approval of the 2025 Equity Incentive Plan, with recommendations from the board indicating strong support for all proposals. Collegium emphasizes its commitment to enhancing shareholder value while adhering to best corporate governance practices, including the independence of board members and rigorous executive compensation policies.

Document Link: View Document